Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
Accrued Liabilities
Arcus Biosciences Inc
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arcus Biosciences Inc
NYSE:RCUS
|
Accrued Liabilities
$64m
|
CAGR 3-Years
28%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$5.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
28%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Arcus Biosciences Inc's Accrued Liabilities?
Accrued Liabilities
64m
USD
Based on the financial report for Mar 31, 2024, Arcus Biosciences Inc's Accrued Liabilities amounts to 64m USD.
What is Arcus Biosciences Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
53%
Over the last year, the Accrued Liabilities growth was 31%. The average annual Accrued Liabilities growth rates for Arcus Biosciences Inc have been 28% over the past three years , 53% over the past five years .